0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Antihypertensive Therapy in the Elderly: Evidence-Based Guidelines and Reality

Franz H. Messerli, MD; Tomasz Grodzicki, MD; Zhanbin Feng, MD
Arch Intern Med. 1999;159(14):1621-1622. doi:.
Text Size: A A A
Published online

Extract

In their thorough analysis of the treatment of hypertension in elderly nursing home residents, Gambassi and colleagues1 concluded that the current prescription pattern with a predominance of calcium antagonists and angiotensin-converting enzyme inhibitors at the expense of β-blockers did not follow recommended guidelines. As an explanation for this discrepancy, they suggest that "the present findings may reflect appropriate prescribing by an enlightened physician facing the difficult applicability of the guidelines to the frail, very old nursing home resident with multiple comorbid conditions and concomitant, complex pharmacological regimens." We can only reemphasize these thoughts. As can be seen in Table 1,26 there is a distinct difference between the "healthy" elderly patients with hypertension (such as those included in the SHEP [Systolic Hypertension in the Elderly Program], Syst-Eur [Systolic Hypertension in Europe], or Syst-China [Systolic Hypertension in the Elderly Chinese Trial] studies) and even the normotensive elderly population, not to speak of nursing home residents. It must be remembered that in the SHEP trial, of each 100 screened patients with isolated systolic hypertension, only 1 was randomized. Thus, most of the clinical trials in the elderly are not dealing with populations that are representative of the general elderly population with hypertension. In addition, the previous Joint National Committee (JNC), the JNC V,7 has erroneously promoted β-blockers as first-line therapy in the elderly, although since then it has become clear that, in the elderly, β-blockers are inappropriate and should no longer be used as initial antihypertensive therapy.8 This means that in the United States alone more than 7 million elderly patients with hypertension still are exposed to the cost, inconvenience, and adverse effects of β-blockers without having any benefits whatsoever. This also means, "mirabile dictu," that we are currently unable to provide evidence-based therapy in the majority of elderly patients with hypertension. The evidence on which the JNC guidelines are based originates from a completely different patient subset and therefore cannot be extrapolated to the 99% of patients who were for one reason or another excluded from participating in the SHEP study. It is perhaps reassuring to note that in the study of Gambassi and colleagues,1 the percentage of patients (8%) receiving β-blockers was remarkably small. Perhaps physicians in that study are trying to teach physicians who write guidelines a lesson on how to more appropriately treat hypertension in the elderly.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();